Niagen Bioscience (NAGE) saw a remarkable increase in its stock value, surging 25.53% in after-hours trading on Wednesday, 6th August 2025. The surge can be attributed to the company’s strong Q2 2025 financial reports that surpassed estimates.
Niagen Bioscience reported Q2 earnings of $0.04 per share, significantly outpacing the estimated $0.01. Likewise, its Q2 revenue of $31.12 million exceeded the estimated $28.32 million, marking a strong growth of approximately 37% from Q2 2024.
The company also revised its FY 2025 revenue outlook upwards, further boosting investor confidence and driving the stock price higher.
